目的：本研究欲深入研究核醫藥物放射核種治療製劑錸-188--錫-1,1-氫氧亞乙基二磷酸鹽（Re-188-HEDP）之特性。材料與方法：核種產生器Re-188孳生器是核能研究所同位素組與國際間合作由美國OakRidge National Laboratory提供。首先進行Re-188-Uigand錯合物之合成及鑑定，並進行Re-188-Uigand製劑中形成之錯化合物成份分析，並探討製劑中配位子（ligand)、還原劑（SnCl??.2H??0）、抗氧化劑（gentisic acid）及pH值大小等因素對錯化合物各成份含量之影響。其次Re-188-Sn-HEDP在各條件下製備之配劑在體外（in vitro）進行特性測定、包含與血中蛋白質的鍵結量及辛醇╱緩衝液（l-octanol/buffer solution）之分占係數之測定，並進行R-188-Ligand錯化合物製劑之生物分佈測定。結果：由實驗結果發現放射性核種治療製劑錸酸鹽R-188-Sn-HEDP配劑使用TSK G2000 PWsize exclusion gel管柱分析可得五個主成份電荷範圍在-1至-3之間，使用Amine A28陰離子交換樹酯管柱分析可得五個主成份電荷範圍在-3至-12之間。當配劑條件改變時放射性核種治療製劑錸酸鹽Re-188-Sn-HEDP主要成份亦有很大的變化。富pH值高於11以上主成份幾乎只呈現一種主成份，pH值愈低酸性愈強時配劑中主成份就有愈多種。結論：因此pH降低可分離出置留時間比較長的主成份出來。至於配位子在配劑中對主成份之影響本研究發現配位子HEDP與還原劑SnCl??2H??0之比例值不同時主成份之含量也會不同。

　　　　　Objective: The goal of this study was to analysis and characterize the agentof rhenium-188-Sn-1,1-hydroxyethylidene diphosphonate in radionuclide therapy forNuclear Medicine.Materials and Methods: We use the generator ofW-188/Re-188 to do some research,because we cooperated with researchers of Institute of Nuclear Energy Research. Thereare the generators of W-188/Re-188 from Oak Ridge National Laboratory in U.S.A..First, We synthesize and identify the rhenium-186-1,1-hydroxyethylidenediphosphonate in different condition, then to analyte (including in different con-ditions) and proceed the biodistribution of the agent of rhenium-188-Sn-1,1-hydroxyethylidene diphosphonate.Results and Discussions: In this study, we found that the main components were fivepeaks by the analytical method of TSK G2000 PW size exclusion gel in HPLC and theircharge is between -1 and -3. The same main components are five peaks by the analyticalmethod of Amine A28 in HPLC and their charge is between -3 and -12 in differentproportions.Conclusion: We found that the component was only one in the high pH of therhenium-188-Sn-1,1-hydroxyethylidene diphosphonate, and the components increasedmore and more when the concentration of hydrogen ion increased. The contents of thecomponents are also dependent on the ratio of the ligand and reduced agent.